Home  |  Contact

UniProtKB/Swiss-Prot P00813: Variant p.Arg76Trp

Adenosine deaminase
Gene: ADA
Variant information

Variant position:  76
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Arginine (R) to Tryptophan (W) at position 76 (R76W, p.Arg76Trp).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and basic (R) to large size and aromatic (W)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In ADASCID.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  76
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  363
The length of the canonical sequence.

Location on the sequence:   LTLPDFLAKFDYYMPAIAGC  R EAIKRIAYEFVEMKAKEGVV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 363 Adenosine deaminase
Site 58 – 58 Important for interaction with adenosine receptors and increasing their affinity for agonists
Site 62 – 62 Important for interaction with adenosine receptors and increasing their affinity for agonists
Mutagenesis 58 – 58 L -> A. Decreases enzyme activity by reducing substrate affinity and maximum velocity; abolishes ADORA1 and ADORA2A modulator function.
Mutagenesis 60 – 60 D -> A. Moderately reduces enzyme activity; reduces ADORA1 and ADORA2A modulation.
Mutagenesis 61 – 61 F -> A. Decreases enzyme activity by reducing maximum velocity; reduces ADORA1 modulation.
Mutagenesis 62 – 62 L -> A. Decreases enzyme activity by reducing substrate affinity and maximum velocity; abolishes ADORA1 and ADORA2A modulator function.
Mutagenesis 64 – 64 K -> A. Moderately reduces enzyme activity; no change in ADORA1 and ADORA2A modulation.
Mutagenesis 65 – 65 F -> A. Decreases enzyme activity by reducing substrate affinity and maximum velocity; reduces ADORA1 and ADORA2A modulation.
Mutagenesis 66 – 66 D -> A. No change in enzyme activity; no change in ADORA1 and ADORA2A modulation.
Mutagenesis 69 – 69 M -> A. Decreases enzyme activity by reducing maximum velocity; reduces ADORA2A modulation.
Helix 76 – 91


Literature citations

Hot spot mutations in adenosine deaminase deficiency.
Hirschhorn R.; Tzall S.; Ellenbogen A.;
Proc. Natl. Acad. Sci. U.S.A. 87:6171-6175(1990)
Cited for: VARIANTS ADASCID TRP-76; PRO-107; GLN-149; CYS-211; THR-215 AND LEU-274;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.